NASDAQIndustrialsManufacturing - Metal FabricationSnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|---|---|
| FY 2027 · Annual | ||
| EBITDA | $3M–$4M | — |
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Execute backlog over next 1-3 years | The company is executing backlog over the next 1-3 years. | Improving | Backlog execution falters causing revenue decline below $34M | Revenue: $9.096M FY2027-Q1; GAAP. Published target: sustain backlog delivery progress over next 3 years. Target period is not explicitly aligned with this observation. Source published Aug 13, 20269,096,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2027-Q1 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 6ff4ef52-9b20-4f1d-9ed4-fb43b8ef1866. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 2 of last 2 quarters. Funded backlog was $52.1M at 2026-Q1 and increased slightly to $52.7M at 2027-Q1. Management expects to deliver this backlog over the next one to three fiscal years with gross margin improvement. The trajectory shows consistent reiteration with stable backlog supporting delivery plans. Delivery assessment Oct 24, 2026 |
Achieve EBITDA growth to $3.0M-$4.0M in fiscal 2027 | A primary condition in TechPrecision Corp's published investment case. The stated target is 3.5 USD_MILLIONS. | Intact | EBITDA falls below $3.0M in fiscal 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 2 of last 2 quarters. EBITDA improved from $239K in 2026-Q1 to $651K in 2027-Q1, a 172% increase quarter-over-quarter. Management maintains FY 2027 guidance for EBITDA growth of +80% to $3.0M-$4.0M. The trajectory shows delivering progress toward the EBITDA growth target. Delivery assessment Oct 24, 2026 |
Improve gross margin to 27% by 2026-Q2 | Gross margin improvement to 27% is a key focus. | Broken | Gross margin falls below 14% by 2026-Q2 | Gross margin: 15.39% FY2027-Q1; GAAP. Published target: 27 PERCENT. Target percentage unit is not explicit. Source published Aug 13, 202615.391381 percent · calculatedSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2027-Q1 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 6ff4ef52-9b20-4f1d-9ed4-fb43b8ef1866. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 2 of last 2 quarters. Consolidated gross margin expanded by 300 basis points in fiscal 2026 with gross profit increasing from $4.3M to $5.0M year-over-year. Management's focus on strategic project mix changes is reflected in improving margin and gross profit, indicating delivering progress. Delivery assessment Oct 24, 2026 |
Grow consolidated revenue to ~$36M in fiscal 2027 | TechPrecision aims to grow revenue to about $36M in fiscal 2027. | Intact | Revenue falls below $34M in fiscal 2027 | Revenue: $9.096M FY2027-Q1; GAAP. Published target: ~36.0 USD_MILLIONS. Target period is not explicitly aligned with this observation. Source published Aug 13, 20269,096,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2027-Q1 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 6ff4ef52-9b20-4f1d-9ed4-fb43b8ef1866. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 2 of last 2 quarters. Revenue increased from $7.4M in 2026-Q1 to $9.1M in 2027-Q1, a 23% increase. Management projects full year 2027 revenue between $35M and $37M, targeting double-digit growth. The trajectory shows delivering progress consistent with stated revenue growth plans. Delivery assessment Oct 24, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Sep 25–Oct 24 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This investment represents a turnaround story, as TPCS is currently loss-making but aims to improve its financial performance over the next few years. The current thesis state is cautious, given recent weak results and high risk.
The market appears to have priced in a low expectation for TPCS, as indicated by its cheap valuation compared to peers. The expectations gap suggests that investors are not anticipating significant improvements in earnings in the near term.
Management is focused on delivering a funded backlog and improving gross margins, which could support better financial results over the next 1-3 years. However, there is a high near-term risk of missing earnings expectations, as TPCS has struggled with consecutive misses recently.
The long-term thesis hinges on the ability of TPCS to execute on its management priorities and the performance of sector bellwethers. If competitors continue to perform well, it could provide a favorable backdrop for TPCS, while any negative guidance from these peers could pose a risk.
In the next 1-3 years, TPCS's success will depend on its execution of strategic priorities and external market conditions. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.